Apollomics Inc. (NASDAQ:APLM) Short Interest Update

Apollomics Inc. (NASDAQ:APLM) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totaling 2,692 shares, a decline of 55.8% from the April 15th total of 6,089 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 4,283 shares, the short-interest ratio is currently 0.6 days.

Apollomics Stock Up 7.3%

NASDAQ APLM traded up $0.99 during trading hours on Friday, hitting $14.59. 12,490 shares of the company’s stock traded hands, compared to its average volume of 5,183. The firm’s 50-day moving average is $16.06 and its 200-day moving average is $17.50. Apollomics has a 52-week low of $3.66 and a 52-week high of $42.12.

Institutional Trading of Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new position in Apollomics Inc. (NASDAQ:APLM) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics as of its most recent filing with the Securities & Exchange Commission. 19.13% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Weiss Ratings cut shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen raised shares of Apollomics from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.